649 institutions hold shares in Sanofi (SNY), with 24.98k shares held by insiders accounting for 0.00% while institutional investors hold 7.04% of the company’s shares. The shares outstanding are 2.51B, and float is at 2.25B with Short Float at 0.32%. Institutions hold 7.04% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Dodge & Cox Inc with over 40.0 million shares valued at $1.94 billion. The investor’s holdings represent 1.59% of the SNY Shares outstanding. As of Dec 30, 2020, the second largest holder is FMR, LLC with 18.79 million shares valued at $912.9 million to account for 0.75% of the shares outstanding. The other top investors are Fisher Asset Management, LLC which holds 18.21 million shares representing 0.72% and valued at over $885.06 million, while Blackrock Inc. holds 0.55% of the shares totaling 13.75 million with a market value of $668.08 million.
Sanofi (NASDAQ: SNY) is 2.14% higher on its value in year-to-date trading and has touched a low of $41.61 and a high of $55.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SNY stock was last observed hovering at around $49.18 in the last trading session, with the day’s gains setting it 0.45% off its average median price target of $61.09 for the next 12 months. It is also 28.9% off the consensus price target high of $69.80 offered by 25 analysts, but current levels are -19.85% lower than the price target low of $41.41 for the same period.
Currently trading at $49.63, the stock is 3.93% and 3.64% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing 0.92% at the moment leaves the stock -0.28% off its SMA200. SNY registered 15.55% gain for a year compared to 6-month loss of -2.28%. The firm has a 50-day simple moving average (SMA 50) of $47.64 and a 200-day simple moving average (SMA200) of $48.95.
The stock witnessed a 8.36% gain in the last 1 month and extending the period to 3 months gives it a 4.31%, and is -0.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.20% over the week and 1.26% over the month.
Sanofi (SNY) has around 99412 employees, a market worth around $123.62B and $43.96B in sales. Current P/E ratio is 8.62 and Fwd P/E is 11.54. Distance from 52-week low is 19.27% and -9.76% from its 52-week high. The company has generated returns on investments over the last 12 months (14.20%).
Sanofi (SNY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Sanofi (SNY) is a “Overweight”. 25 analysts offering their recommendations for the stock have an average rating of 1.50, where 8 rate it as a Hold and 3 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Sanofi is expected to release its quarterly report on 04/28/2021 and quarterly earnings per share for the current quarter are estimated at $0.87 with sales reaching $10.24B over the same period.The EPS is expected to grow by 324.80% this year, but quarterly earnings will post 7.00% year-over-year. Quarterly sales are estimated to grow 3.50% in year-over-year returns.
Sanofi (SNY) Insider Activity
The most recent transaction is an insider purchase by Sanofi, the company’s 10% Owner. SEC filings show that Sanofi bought 81,250 shares of the company’s common stock on Jul 28 at a price of $16.00 per share for a total of $1.3 million. Following the purchase, the insider now owns 0.52 million shares.
Sanofi disclosed in a document filed with the SEC on Jun 09 that Sanofi (10% Owner) sold a total of 120,234 shares of the company’s common stock. The trade occurred on Jun 09 and was made at $597.48 per share for $71.84 million. Following the transaction, the insider now directly holds 0.28 million shares of the SNY stock.
Still, SEC filings show that on May 29, Sanofi (10% Owner) disposed off 2,399,552 shares at an average price of $509.85 for $1.22 billion. The insider now directly holds 400,000 shares of Sanofi (SNY).
Sanofi (SNY): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 37.93% up over the past 12 months and Johnson & Johnson (JNJ) that is 30.31% higher over the same period. Bristol-Myers Squibb Company (BMY) is 22.37% up on the 1-year trading charts. Short interest in the company’s stock has risen 9.82% from the last report on Feb 11, 2021 to stand at a total of 6.43 million short shares sold with a short interest ratio of 3.29.